|
Type | Nanomaterials | Drugs delivered | Disease | Findings | Disadvantages | References |
|
Lipid-based nanomaterials | Prp CsiRNA-RVG-9r-liposomes | Prp CsiRNA RVG-9rPrp Cs | Neurodegenerative protein misfolding diseases (NPMD) | Increase delivery efficiency, prolong half-life of drug in peripheral circulation, and increase BBB passage rate. | In animal experiments, mice treated with nanomaterials have a certain probability of causing type III acute allergic reaction. | [18] |
Fus-liposomes-rhFGF20 | rhFGF20 | Parkinson’s disease (PD) | Extend drug half-life, high encapsulation rate, increase BBB penetration ability, slow-release drugs, targeting, high biocompatibility. | Not mentioned. | [19] |
RVG29-liposomes | N-3,4-Bis(pivaloyloxy)-dopamine | PD | High BBB penetrability, high biocompatibility, striatum nigra targeting, drug sustained release. | Not mentioned. | [20] |
PEG-liposomes-MBs | GDNF+Nurr1 | PD | Ultrasound-guided ability, ultrasound-guided BBB penetration ability, sustained release, and extended drug half-life. | Poor BBB penetration. | [21] |
RMP7-lf-PEG-liposomes | Quercetin | Alzheimer’s disease (AD) | High BBB penetration ability, SK-N-MC cell targeting, drug sustained release. | May be able to induce inflammation. | [22] |
NGF-SM-ApoE-liposomes | Nerve growth factor, surface serotonin modulator, ApoE | AD | Maintain NGF activity, high biocompatibility, high BBB permeability, Aβ1-42 and SK-N-MC cell targeting, sustained release of contents. | Not mentioned. | [23] |
Polymeric nanomaterials | Nanomicellar system (SANS) | L-DOPA | PD | Autonomous formation, easy to manufacture, epidermal permeability, drug sustained release. | Lack of targeting. | [24] |
LD crystalsomes (micellar) | L-DOPA | PD | Autonomous formation, easy to manufacture, drug sustained release, good biocompatibility, higher drug delivery efficiency. | The biological toxicity is not clear. | [25] |
Pluronic P85/F68 micelles | Baicalein | PD | Self-forming, stable character suitable for oral administration, sustained release, enhance content of crossing BBB capacity, enhance content of cell accumulation. | Weak BBB permeability, may cause damage to the structure and function of mitochondria. | [26] |
Mixed-shell polymeric micelle (MSPM) | None | AD | Aβ deposits are targeted, Aβ deposits have strong affinity, reduce the production of proinflammatory factors, have good BBB permeability and strong biocompatibility. | Longer metabolic time. | [27] |
C(NCAM-C3)T(TPP)-N(nano)M(micelle) | Resveratrol | AD | Automated assembly, good BBB permeability, high encapsulation efficiency, mitochondrial targeting, cumulative, drug sustained release, reduce expression of proinflammatory factors. | Longer metabolic time. | [28] |
Micelle | Curcumin | AD | Automatic formation, good drug encapsulation rate, drug sustained release, BBB permeability. | Not targeted itself. | [29] |
PAMAM dendrimers | Carbamazepine | Neurodegeneration (ND) | Improve the solubility of the package, increase the stability of the package, good drug packaging ability, reduce the package of peripheral and cellular toxicity, good biocompatibility. | Not resistant to acid and alkali, high concentration, easy to kill, drug sustained release ability is poor. | [30] |
G4HisMal-dendrimers | Boc-L-histidine | AD | High BBB permeability, good biocompatibility, Aβ (1 − 40) targeting. | Not mentioned. | [31] |
Lactoferrin coupled PAMAM dendrimers (PAMAM-lf) | Memantine | AD | Drug sustained release, controlled release, extended drug half-life, good encapsulation ability, high drug delivery efficiency, good BBB penetration, and brain targeting. | Have some blood toxicity. | [32] |
Phosphorus dendrimers | Phosphorus | PD | Some anti-HIV ability, inhibition of -SYN fibrosis. | Hematotoxicity. | [33] |
Carbosilane dendrimers | None | PD | Inhibits ASN fibrillation, reduces ROS, and protects nerve cells. | Not mentioned. | [34] |
Dopamine-loaded PLGA nanomaterials | Dopamine | PD | Prolonged half-life, slow-release, controlled-release, decreased peripheral circulation toxicity, good biocompatibility, decreased Ros, striatum targeting, BBB permeability. | Cause inflammation in the targeted area. | [35] |
Collagen-coated PLGA | None | PD | Good cell adhesion, good biocompatibility, and certain ability to promote cell growth. | Not mentioned. | [36] |
PLK2-PLGA-NP | PLK2 | PD | Inhibition of drug degradation, improvement of enzyme stability and long-term drug release, good biocompatibility and strong encapsulation ability. | Not mentioned. | [37] |
Fe3O4-PEG/PLGA-OX26 | Magnetic Fe3O4 nanoparticles, OX26 | AD | Strong drug loading, magnetic targeting, biocompatibility, sustained release, controlled release. | Larger particles. | [38] |
Inorganic nanomaterials | Hollow gold nanoparticles | Xanthoceraside | ND | Large drug loading, increased drug solubility, can be traced. | No targeted ability | [39] |
Hollow au/Ag nanostars | None | ND | Large surface area, high Raman spectrum activity, and high near-infrared light sensitivity. | Unknown biological toxicity. | [40] |
Concave cubic Qu-P80-AuPd | Quercetin | AD | Good biocompatibility, good BBB penetration, high loading capacity, low cytotoxicity, good biocompatibility, lysosomal targeting. | Not mentioned. | [41] |
GNRs-APH-scFv, GAS | Thermophilic acylpeptide hydrolase | AD | Good biocompatibility, strong photothermal effect, near infrared light sensitivity, low toxicity, stable physical and chemical properties. | Self-BBB penetration is slightly worse. | [42] |
Single-wall carbon nanotubes and gold nanoparticles modified screen-printed electrodes | None | PD (dopamine monitoring) | High sensitivity, good stability, small damage, real-time monitoring. | Not mentioned. | [43] |
Functionalized random networks of carbon nanotube RN-CNT | None | PD (early diagnosis) | High sensitivity, high detection accuracy, high degree of integration of DOPA. | Not mentioned. | [44] |
Carbon nanotubes (CNTs) | None | PD | Reduce glial cell proliferation, increase stem cell proliferation, good biocompatibility. | Not mentioned. | [45] |
SWCNT-PEGs-lf | L -1 6-hydro--xydopamine | PD | Striatal targeting, high biocompatibility, good BBB permeability, strong drug loading capacity, low toxicity, sustained release. | Cause a certain inflammatory response. | [46] |
EMT nanomaterials | None | AD | Inhibition of fibrinogen interactions in abnormal clots. | Not mentioned. | [47] |
SBA-15 (silica holed nanorod) | L-DOPA | PD | Has good BBB permeability, good drug loading, and good biocompatibility. | No targeted ability. | [48] |
|